ReviewNature reviews. Urology2020
Financial toxicity associated with treatment of localized prostate cancer.
Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Subjective and objective financial toxicity among colorectal cancer patients: a systematic review.BMC cancer · 2024Pooled it
- A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).BMC cancer · 2023Trial
- Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial.International journal of radiation oncology, biology, physics · 2021Trial
- Association of Travel Time With Definitive Prostate Cancer Treatment: A United States Registry Cohort Study.Cancer medicine · 2026Article
- Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study.Annals of surgical oncology · 2026Article
- Financial toxicity and its association with quality of life and psychological distress among patients with gynecologic cancers receiving radiotherapy in China: a multicenter cross-sectional study.Frontiers in public health · 2026Article
- Financial toxicity and distress among prostate cancer patients in Lebanon: a cross-sectional study.Frontiers in public health · 2026Article
- Article
- A Phase 1 Trial of Image Guided Risk Volume-Adapted Postprostatectomy Radiation Therapy.International journal of radiation oncology, biology, physics · 2025Article
- Quantifying Suicide Risk in Prostate Cancer: A SEER-Based Predictive Model.Journal of epidemiology and global health · 2025Article
- Article
- Article
- A sustainable and expedited 'One-Stop' prostate cancer diagnostic pathway to reduce environmental impact and enhance accessibility.BJUI compass · 2024Article
- WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling.Medical oncology (Northwood, London, England) · 2024Article
- Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes.Advances in therapy · 2024Review
- Anticipatory Guidance: Developing a Patient Navigation Pathway to Reduce the Financial Toxicity of Cancer.Medical research archives · 2023Article
- Developing a Conceptual Framework for Socioeconomic Impact Research in European Cancer Patients: A 'Best-Fit' Framework Synthesis.The patient · 2023Article
- A prospective evaluation of patient perspectives and financial considerations during prostate cancer treatment decision-making.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- New technology in prostate cancer and financial toxicity.Urologic oncology · 2023Review
- A Systematic Review of New Imaging Technologies for Robotic Prostatectomy: From Molecular Imaging to Augmented Reality.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Financial toxicity is a broad term to describe the economic consequences and subjective burden resulting from a cancer diagnosis and treatment. As financial toxicity is associated with poor disease outcomes, recognition of this problem and calls for strategies to identify and support those most at risk are increasing. Men with localized prostate cancer face treatment choices including active surveillance, prostatectomy or radiotherapy. The fact that potential patient out-of-pocket costs might influence decision making has rarely been acknowledged and, overall, the risk of financial toxicity for men with localized prostate cancer remains poorly studied. This shortfall requires a work-up in the context of prostate cancer and a multidimensional framework for considering a patient's risk of financial toxicity. The major elements of this framework are direct and indirect costs, patient-specific values, expectations of possible financial burdens, and individual economic circumstances. Current data indicate that total cost patterns probably differ by treatment modality: surgery might have an increased short-term effect, whereas radiotherapy might have an increased long-term risk of financial toxicity. Specific thresholds of patient income levels or out-of-pocket costs that predict risk of financial toxicity are difficult to identify. Compared with other malignancies, prostate cancer might have a lower overall risk of financial toxicity, but persistent post-treatment urinary, bowel or sexual adverse effects are likely to increase this risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.